An HQ with a View

Our biopharma
partnerships

0+
Partners
0+
Clinical Trials
0+
Drugs
Overview

Adaptive works with over 175 biopharmaceutical partners in hundreds of trials per year across the research and development value chain to incorporate proven immune-driven metrics and screening capabilities into translational analyses, diagnostic tools and drug discovery efforts.

Comprehensive use cases across drug development process

We work collaboratively to elucidate mechanism of action and dosing for earlier phase clinical trials, identify biomarkets of efficacy or adverse events for later stage trials, and for drug candidates that utilize or leverage the acumen of the immune system.

Graphic showing the journey from Discovery to Preclinical to Clinical
Logo for Amgen
Logo for Genentech
Logo for Microsoft
Logo for illumina
Logo for Foundation Medicine
Logo for LabCorp
Logo for Roche
Logo for Genentech
Icons of people communicating
Flexible partnering models
Icons of people communicating

In all our partnering models, Adaptive provides end-to-end support including hypothesis-driven trial design, extensive data analyses, parallel regulatory support when necessary, compliant data transfer and novel target screening.

Our models range from fee-for-service to diagnostic partnering to data generation for discovery purposes.

Reach out and we can work with you on how our immune medicine platform can accelerate your drug discovery and development efforts.

Icons of people communicating
End-to-end support

We work collaboratively to elucidate mechanism of action and dosing for earlier phase clinical trials, identify biomarkers of efficacy or adverse events for later stage trials, and screen for drug candidates that utilize or leverage the acumen of the immune system. In all our partnering models, Adaptive provides end-to-end support including hypothesis-driven trial design, extensive data analyses, parallel regulatory support, compliant data transfers, and novel target screening.